Literature DB >> 11589671

Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment.

A J Dickinson1, P Perros.   

Abstract

Despite many learned publications over recent decades, the assessment of active thyroid-associated orbitopathy (TAO) remains difficult and controversial. There are no biochemical, immunological or imaging investigations which can identify active disease reliably, and clinical assessment is still of paramount importance. We therefore review the strengths and weaknesses of all methods of clinical assessment. A new atlas for clinical assessment of soft tissue signs has been developed, and its reproducibility assessed. It details a suggested protocol that could help standardize descriptions of TAO and allow more objective assessment of its activity and severity. This is relevant to general endocrinologists, who have a crucial role in the identification of patients who require ophthalmological assessment. Certain aspects are more relevant to ophthalmologists and endocrinologists who have a special clinical and research interest in TAO. Unless a reproducible system of assessment is devised and widely adopted, it will remain difficult to interpret research meaningfully, particularly if results appear to contradict.

Entities:  

Mesh:

Year:  2001        PMID: 11589671     DOI: 10.1046/j.1365-2265.2001.01349.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  25 in total

Review 1.  Recent developments in thyroid eye disease.

Authors:  Tom Cawood; Paul Moriarty; Donal O'Shea
Journal:  BMJ       Date:  2004-08-14

2.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

Review 3.  Graves orbitopathy: a perspective.

Authors:  Petros Perros; Gerasimos E Krassas
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

4.  Therapy: evidence-based treatment of Graves ophthalmopathy.

Authors:  Wilmar M Wiersinga
Journal:  Nat Rev Endocrinol       Date:  2009-12       Impact factor: 43.330

5.  Quantitative analysis of orbital soft tissues on computed tomography to assess the activity of thyroid-associated orbitopathy.

Authors:  Jun Soo Byun; Nam Ju Moon; Jeong Kyu Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-12       Impact factor: 3.117

6.  Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg.

Authors:  Letterio Salvatore Politi; Claudia Godi; Gabriella Cammarata; Alessandro Ambrosi; Antonella Iadanza; Roberto Lanzi; Andrea Falini; Stefania Bianchi Marzoli
Journal:  Eur Radiol       Date:  2014-02-12       Impact factor: 5.315

7.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

8.  Inflammatory swelling of the inferior oblique muscle in thyroid associated ophthalmopathy.

Authors:  Hirohiko Kakizaki
Journal:  Clin Ophthalmol       Date:  2007-06

9.  Diagnostic accuracy of short-time inversion recovery sequence in Graves' Ophthalmopathy before and after prednisone treatment.

Authors:  Fabio Tortora; Mariaevelina Prudente; Mario Cirillo; Andrea Elefante; Maria Paola Belfiore; Francesco Romano; Salvatore Cappabianca; Carlo Carella; Sossio Cirillo
Journal:  Neuroradiology       Date:  2014-02-27       Impact factor: 2.804

10.  Update on thyroid eye disease and management.

Authors:  Erick D Bothun; Ryan A Scheurer; Andrew R Harrison; Michael S Lee
Journal:  Clin Ophthalmol       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.